Beyond Air, Inc. reported a significant increase in revenues by 157% to $1.8 million for the fiscal first quarter ended June 30, 2025.
The company secured a national group purchasing agreement for therapeutic gases with Premier, Inc., a network with over 4,350 member hospitals and health systems.
Revenue guidance for fiscal year 2026 was reaffirmed at $12-$16 million.
Revenue Growth
Revenue increased by 157% to $1.8 million compared to $0.7 million in the same period last year.
International Expansion
International revenue from LungFit PH system and Smart Filter sales continues to accelerate with recent regulatory approvals across Europe, the Middle East, and Asia.
Regulatory Milestones
A PMA supplement for the second-generation LungFit PH was submitted to the U.S. FDA in June 2025.
Clinical Development
Phase 1a and 1b trials are ongoing for the intratumoral ultra-high concentration Nitric Oxide technology for solid tumors.
NeuroNOS Program
Development of nNOS inhibitors for the treatment of autism spectrum disorder and other neurological conditions is progressing, with Orphan Drug Designation granted to BA-102.
- The company's strong market adoption of LungFit PH resulted in sequential revenue growth of approximately 50%.
- Expansion into international markets and regulatory approvals are fueling revenue growth and market reach for Beyond Air.
- Progress in clinical trials and the development of novel therapies for neurological disorders showcase the company's commitment to innovation.
Beyond Air, Inc. demonstrates robust financial performance and strategic growth initiatives in the medical device and biopharmaceutical sector, supported by positive revenue trends and advancements in clinical development programs.